New drug combo trial offers hope for advanced liver cancer patients
NCT ID NCT06530251
Summary
This study is testing a new drug called AK112, given alone or in combination with other treatments, for people with advanced liver cancer. The first part checks safety and finds the right dose, while the second part compares AK112 treatments to current standard care. Researchers want to see if these treatments can shrink tumors and help patients live longer with manageable side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)
RECRUITINGJinan, Shandong, China
Contact
Conditions
Explore the condition pages connected to this study.